JP Morgan Put 405 VRTX 18.10.2024/ DE000JK3LHS4 /
| 2024-07-24 10:39:05 AM | Chg.- | Bid10:20:07 AM | Ask10:20:07 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.340EUR | - | 0.330 Bid Size: 1,000 |
0.630 Ask Size: 1,000 |
Vertex Pharmaceutica... | 405.00 USD | 2024-10-18 | Put |
GlobeNewswire
06-28
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Di...
GlobeNewswire
06-10
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as C...
GlobeNewswire
05-15
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-09
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
05-08
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-08
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...
GlobeNewswire
05-07
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
04-30
American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Dis...
GlobeNewswire
04-27
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN
GlobeNewswire
04-22
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire
04-22
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...
GlobeNewswire
04-09
American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated...
